Companies › Jiangsu Jingze Biopharmaceutical
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Human Truncated Plasmin Injection (JZB32) Serine protease (truncated plasmin) that cleaves fibrin and other extracellular matrix pro | PLG | Phase 2 | Vitreomacular Traction (VMT) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07910630 | Recombinant Human Truncated Plasmin Injection (JZB32) | Phase 2 | Vitreomacular Traction (VMT) | Ophthalmology | Dec 2027 |
Qlaris Bio Aperta Biosciences ONL Therapeutics BioTheraVision Ascension Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.